IL28B rs12979860 and rs8099917 polymorphisms in patients with chronic hepatitis C and non-viral liver disease

Creative Commons License

ÇAKAL B., ÇAVUŞ B., Atasoy A., ALTUNOK D., PODA M., BULAKÇI M., ...Daha Fazla

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, sa.10, ss.1131-1136, 2022 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4328/acam.21274
  • Dergi Adı: ANNALS OF CLINICAL AND ANALYTICAL MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.1131-1136
  • Anahtar Kelimeler: Interleukin 28B, Chronic Hepatitis C, Non-Viral Liver Disease, Treatment Response, HEPATOCELLULAR-CARCINOMA, INTERLEUKIN-28B GENE, ASSOCIATION, FIBROSIS
  • İstanbul Üniversitesi Adresli: Evet

Özet

Aim: In this study, we aimed to evaluate the relationship of IL28B rs12979860 and rs8099917 polymorphisms with the clinical, histological and virological outcomes of patients with chronic hepatitis C and non-viral liver disease, and also the treatment responses of patients with chronic hepatitis C, who received direct-acting antiviral (DAA) therapy. Material and Methods: A total of 142 patients, 59 of whom had chronic hepatitis C, and 83 of whom had liver biopsy for different clinical indications, were included in the study. The IL28B rs12979860 and rs8099917 polymorphism were genotyped using the TaqMan assay. Results: IL28B rs12979860 CC and IL28B rs8099917 TT were identified as the genotypes with the highest frequency in all patients, and patient groups included in the study. On the other hand, IL28B rs12979860 TT and IL28B rs8099917 GG were the genotypes with the lowest frequency. No significant association was found between IL28B rs12979860 and IL28B rs8099917 polymorphisms and clinical and histopathological outcomes of patients as well as DAA treatment responses in patients with hepatitis C. Discussion: IL28B rs12979860 and rs8099917 polymorphisms do not affect clinical and histopathological outcomes of patients with chronic hepatitis C and non-viral liver diseases as well as with DAA treatment.